Immune Based Articles & Analysis
16 news found
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
MiXCR 4.0 is enhanced software for analysis of genomics data and building a comprehensive picture of the immune response. Leading pharmaceutical research and development (R&D) teams can leverage MiXCR 4.0 for drug discovery pipelines, and for analyzing DNA sequencing data unraveling genomic information about antibodies, T-cell, and B-cell receptors. ...
Liaison Memed Bv is an immune system based protein signature test for distinguishing between bacterial and viral infections The test was developed following the licensing agreement signed with Memed as announced in September 2020 The new test is available on the Liaison Xl platforms in countries that accept CE mark and U.S. food and drug administration ...
ByMeMed
We are planning to study the peak immunity of GP2 and how to assess when to administer booster injections. ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
(Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS ...
Orally available Alphataxin, is the first and only drug in development to increase formation of CD4+ helper T cells. Immune checkpoint inhibitor therapy, the vanguard of cancer therapy, promotes the ability of CD8+ T cells to kill tumor cells. ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
The second manuscript has been published in “Vaccine” and provides important data validating the potential of V-306 to be administered ‘epicutaneously’ via skin patch delivery, as a method to boost protective immunity to RSV following initial intramuscular injection. Following administration of V-306, the immune response is characterized ...
The advantages of protein body-based vaccines include the large amounts of antigens that can be delivered to the body and their nanoparticulate architecture for induction of potent immune responses. Moreover, vaccines based on protein bodies are very fast and cost-effective to produce. ...
Today, Immunai launches out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. ...
ByImmunai
NHLBI also supports the National Asthma Education and Prevention Program , which translates research discoveries into improved clinical practice and quality of life for patients with asthma. Asthma and the Immune System NIAID-supported research focuses on understanding the immune system’s role in asthma and on identifying new strategies to treat and ...
On Tuesday, March 4, Dako will co-host an Exhibitor Seminar in cooperation with one of its pharmaceutical partners, Bristol-Myers Squibb, titled "Exploring Immune-Based Biomarkers in Oncology," from 5:30-7:30 p.m. in Room 29D. This seminar will update the pathology community on the importance of emerging immune therapies for the treatment of ...
NIAID's Inner-City Asthma Consortium designs and implements immune-based therapies for asthma and conducts studies to define and treat the disease in inner-city children. ...